A company based in nearby Berwyn is at work researching answers to the problem of traumatic brain injury (TBI). The U.S. Army has given a $3 million grant to QR Pharma, a five-year-old startup, to study the effects of a compound known as Posiphen in mice. The study will be conducted in two different trials, partnering with University of California Los Angeles. Doctors David Hovda and Marie-Francoise Chesselet are part of the research team.
The Department of Defense’s Defense and Veterans Brain Injury Center (DVBIC) is the Department of Defense’s Office of Responsibility for recording and tracking traumatic brain injury (TBI) data in the U.S. military, wherever U.S. service personnel are located. According to the DVBIC, over 80 percent of TBI cases occur outside of war zones. According to the DVBIC website, a variety of causes contribute to TBI in military personnel, including military training, vehicle collisions involving both military and privately owned vehicles, and sports-related accidents.
QR Pharma, in seeking funding to develop drugs for Parkinson’s disease and Alzheimer’s disease, has also attracted attention and help from well-known people and organizations. The company also received nearly a half-million dollars from the Michael J. Fox Foundation for Parkinson’s Research (MJFF). The money was designated for research on a compound that could be a treatment for Parkinson’s. The study will be led by an associate professor of psychiatry from Massachusetts General Hospital’s genetic and aging research department, Jack T. Rogers, and by Dr. Robert Nussbaum of the University of California, San Francisco.
While the research on traumatic brain injury continues in Berwyn, Philadelphia, residents can get help in seeking to recover damages for their pain, suffering and medical expenses by consulting a professional with experience in the area of brain injuries.
philly.com, “Berwyn’s QR Pharma gets $3 million from U.S. Army for traumatic brain injury study” David Sell, Oct. 09, 2013